When Hong Kong unveiled plans last year to encourage biotech companies to list in the city by loosening listing rules, the financial industry and investors cheered. Hong Kong was an obvious financing center for a growing number of Chinese companies developing new drugs. …read more
Source:: Yahoo Finance
